
Bambusa Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibodies for immunology and inflammation.
Bambusa Therapeutics is a clinical-stage biopharmaceutical company developing long-acting bispecific antibodies for immunology and inflammation, with clinical programs in atopic dermatitis, other inflammatory skin diseases, and Type 2 inflammatory disorders. Its pipeline includes BBT001, targeting IL-4Rα and IL-31 for atopic dermatitis and other inflammatory skin diseases, and BBT002, targeting IL-4Rα and IL-5 for Type 2 inflammatory disorders.
The company combines antibody engineering with clinically and commercially validated biologic pathways into single molecules formulated for high-concentration subcutaneous delivery, improving durability and convenience beyond existing monotherapies.
Similar Company · Competitor

ReViral
Competitor

Ironshore Pharmaceuticals
Competitor

TORL BioTherapeutics

Cantai Therapeutics
cantaitx.com

Kenjockety Biotechnology
kenjocketybio.com

Climb Bio
climbbio.com

Bicara Therapeutics
bicara.com

Upstream Bio
upstreambio.com

Attovia Therapeutics
attovia.com

LiliumX
liliumx.com

Amagma

Infinimmune
infinimmune.com

Amberstone Biosciences
amberstonebio.com

Rondo Therapeutics
rondotx.com

XBiotech
xbiotech.com

Bespoke Biotherapeutics
bespokebiotx.com

Ancora Biotech
ancorabiotech.com

Narval
narvalbio.com

Walking Fish Therapeutics
walkingfishtx.com

IGM Biosciences
igmbio.com
Companies similar to Bambusa Therapeutics include ReViral, TORL BioTherapeutics, Cantai Therapeutics and Kenjockety Biotechnology.
Bambusa Therapeutics was founded in 2024.
Bambusa Therapeutics' headquarters is located in Boston, MA, US.
Bambusa Therapeutics' most recent funding round was for $53.3M (USD) in February 2025.
As of Feb 12, 2025, Bambusa Therapeutics has disclosed funding of $53.3M (USD).